Stock listing
NASDAQ:LFWD Lifeward Ltd. Stock
Home listing (NASDAQ) of Lifeward Ltd.
Follow Lifeward Ltd. into a list and get an email when it puts out news.
Share price · NASDAQ:LFWD
$2.80 USD -0.40 (-12.4%)
Close on Nov 20, 2026
- Day range
- $2.73 – $2.98 USDNov 20, 2026
- Volume
- 35,411 sharesNov 20, 2026
- Market cap
- $7.94M USDAt the close on Nov 20, 2026 · price × 2.83M shares outstanding
- 52-week range
- $2.73 – $9.61 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $68,807 USDMedian day 5,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LFWD · Home | $2.803 USD | -0.397 (-12.4%) | 35,411 | $2.80 | $2.98 | $2.73 | $3.20 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LFWD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.803 | -0.397 | -12.4% | $2.80 | $2.98 | $2.73 | 35,411 | |
| $3.20 | +0.10 | +3.2% | $3.08 | $3.40 | $3.04 | 13,371 | |
| $3.10 | -0.52 | -14.4% | $3.46 | $3.52 | $3.10 | 32,433 | |
| $3.62 | -0.44 | -10.8% | $4.03 | $4.17 | $3.39 | 31,679 | |
| $4.06 | -1.66 | -29.0% | $5.42 | $5.42 | $3.81 | 30,400 | |
| $5.72 | -0.04 | -0.7% | $5.71 | $5.77 | $5.54 | 5,500 | |
| $5.76 | -0.085 | -1.5% | $5.84 | $5.969 | $5.75 | 5,900 | |
| $5.845 | -0.095 | -1.6% | $5.88 | $5.955 | $5.80 | 6,600 | |
| $5.94 | +0.13 | +2.2% | $5.97 | $6.18 | $5.91 | 2,100 | |
| $5.81 | +0.07 | +1.2% | $5.65 | $5.964 | $5.65 | 5,000 | |
| $5.74 | -0.32 | -5.3% | $5.97 | $6.10 | $5.74 | 55,400 | |
| $6.06 | +0.23 | +3.9% | $6.05 | $6.17 | $5.98 | 22,900 | |
| $5.83 | -0.23 | -3.8% | $6.02 | $6.16 | $5.82 | 49,600 | |
| $6.06 | +0.108 | +1.8% | $5.95 | $6.29 | $5.925 | 94,500 | |
| $5.952 | +0.042 | +0.7% | $5.87 | $6.10 | $5.87 | 3,500 | |
| $5.91 | +0.16 | +2.8% | $5.91 | $5.91 | $5.91 | 1,100 | |
| $5.75 | -0.29 | -4.8% | $5.80 | $6.15 | $5.75 | 22,800 | |
| $6.04 | +0.23 | +4.0% | $5.98 | $6.26 | $5.85 | 12,800 | |
| $5.81 | -0.25 | -4.1% | $6.10 | $6.10 | $5.81 | 8,500 | |
| $6.06 | +0.243 | +4.2% | $5.64 | $6.06 | $5.64 | 23,200 | |
| $5.817 | +0.317 | +5.8% | $5.566 | $5.93 | $5.46 | 84,000 | |
| $5.50 | -0.11 | -2.0% | $5.52 | $5.61 | $5.45 | 4,300 | |
| $5.61 | -0.32 | -5.4% | $5.80 | $5.80 | $5.61 | 1,800 | |
| $5.93 | -0.07 | -1.2% | $6.16 | $6.20 | $5.88 | 6,400 | |
| $6.00 | -0.06 | -1.0% | $6.13 | $6.53 | $6.00 | 23,900 | |
| $6.06 | -0.16 | -2.6% | $6.07 | $6.07 | $6.06 | 1,200 | |
| $6.22 | +0.12 | +2.0% | $6.15 | $6.25 | $6.15 | 800 | |
| $6.10 | -0.12 | -1.9% | $6.102 | $6.17 | $6.05 | 10,200 | |
| $6.22 | -0.27 | -4.2% | $6.446 | $6.461 | $6.22 | 1,700 | |
| $6.49 | +0.06 | +0.9% | $6.30 | $6.61 | $6.10 | 3,700 | |
| $6.43 | -0.07 | -1.1% | $6.30 | $6.50 | $6.10 | 5,000 | |
| $6.50 | +0.16 | +2.5% | $6.10 | $6.50 | $6.10 | 2,900 | |
| $6.34 | -0.33 | -4.9% | $6.66 | $6.80 | $6.10 | 10,000 | |
| $6.67 | +0.82 | +14.0% | $6.04 | $6.70 | $6.04 | 10,400 | |
| $5.85 | -0.11 | -1.8% | $5.903 | $6.35 | $5.85 | 6,100 | |
| $5.96 | -0.641 | -9.7% | $5.43 | $6.48 | $5.18 | 11,900 | |
| $6.601 | -0.309 | -4.5% | $6.91 | $6.91 | $6.552 | 4,500 | |
| $6.91 | -0.01 | -0.1% | $6.92 | $6.92 | $6.91 | 1,000 | |
| $6.92 | -0.07 | -1.0% | $7.00 | $7.00 | $6.92 | 6,000 | |
| $6.99 | +0.02 | +0.3% | $6.94 | $6.99 | $6.94 | 900 | |
| $6.97 | -0.04 | -0.6% | $7.10 | $7.114 | $6.95 | 7,900 | |
| $7.01 | +0.07 | +1.0% | $7.00 | $7.01 | $6.95 | 6,400 | |
| $6.94 | -0.06 | -0.9% | $6.90 | $7.18 | $6.90 | 2,000 | |
| $7.00 | +0.08 | +1.2% | $7.16 | $7.16 | $6.75 | 2,100 | |
| $6.92 | -0.04 | -0.6% | $7.10 | $7.20 | $6.92 | 5,300 | |
| $6.96 | +0.05 | +0.7% | $6.92 | $7.19 | $6.90 | 6,600 | |
| $6.91 | -0.16 | -2.3% | $7.322 | $7.322 | $6.91 | 5,000 | |
| $7.07 | -0.04 | -0.6% | $7.35 | $7.35 | $7.01 | 7,100 | |
| $7.11 | -0.01 | -0.1% | $7.254 | $7.254 | $6.869 | 10,300 | |
| $7.12 | -0.01 | -0.1% | $7.39 | $7.39 | $7.12 | 900 | |
| $7.13 | -0.27 | -3.6% | $7.12 | $7.15 | $7.12 | 2,400 | |
| $7.40 | 0.00 | 0.0% | $7.40 | $7.40 | $7.40 | 389 | |
| $7.40 | +0.42 | +6.0% | $6.99 | $7.40 | $6.99 | 4,300 | |
| $6.98 | -0.12 | -1.7% | $7.105 | $7.105 | $6.98 | 7,600 | |
| $7.10 | -0.16 | -2.2% | $7.27 | $7.332 | $7.03 | 4,200 | |
| $7.26 | +0.06 | +0.8% | $7.21 | $7.26 | $7.10 | 3,500 | |
| $7.20 | -0.45 | -5.9% | $7.53 | $7.575 | $7.20 | 5,600 | |
| $7.65 | +0.19 | +2.5% | $7.47 | $7.683 | $7.41 | 5,400 | |
| $7.46 | +0.095 | +1.3% | $7.30 | $7.50 | $7.20 | 4,400 | |
| $7.365 | -0.125 | -1.7% | $7.535 | $7.67 | $7.365 | 5,300 | |
| $7.49 | +0.10 | +1.4% | $7.30 | $7.49 | $7.30 | 2,500 | |
| $7.39 | +0.10 | +1.4% | $7.39 | $7.54 | $7.282 | 3,800 | |
| $7.29 | -0.03 | -0.4% | $7.415 | $7.475 | $7.10 | 9,500 | |
| $7.32 | -0.01 | -0.1% | $7.41 | $7.505 | $7.32 | 8,900 | |
| $7.33 | +0.06 | +0.8% | $7.36 | $7.37 | $7.19 | 6,000 |
Splits
3 splits since 2019 · NASDAQ:LFWD · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation | |
| 1-for-7 | Consolidation | |
| 1-for-25 | Consolidation |
- Ticker
- NASDAQ:LFWD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
Lifeward Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest earnings call · May 15, 2026
Lifeward (NASDAQ:LFWD) Q1 2026 Earnings Call
Replay and transcript
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 17 slides
Latest news
Lifeward Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 13, 2026
Closed $4.06 (-29.0%) on Nov 13, 2026
Lifeward’s ReWalk® Personal Exoskeleton Demonstrates Sustained Long-Term Home Use and Patient Satisfaction in Latest Independent Peer-Reviewed Study
Oct 14, 2026
Closed $6.22 (+2.0%) on Oct 14, 2026
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
Sep 8, 2026
Closed $7.40 (+6.0%) on Sep 8, 2026
Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer
Aug 31, 2026
Closed $7.20 (-5.9%) on Sep 1, 2026
Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth
Aug 14, 2026
Closed $7.45 (-5.6%) on Aug 14, 2026
Lifeward to Report Second Quarter 2026 Financial Results on August 14, 2026
Aug 7, 2026
Closed $7.69 (+3.9%) on Aug 7, 2026
Lifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk® Personal Exoskeleton
Aug 5, 2026
Closed $7.25 (+0.6%) on Aug 5, 2026
Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing
Jul 7, 2026
Closed $8.12 (-3.9%) on Jul 8, 2026
Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
May 19, 2026
Closed $6.40 (-2.7%) on May 19, 2026
Lifeward Reports First Quarter 2026 Financial Results
May 15, 2026
Closed $6.70 (+1.6%) on May 15, 2026
Lifeward Ltd. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 25 in the last 12 months · 179 in all · newest Nov 13, 2026 · oldest 2019
- Calls
- 10 calls with a replay · 10 with a transcript · latest May 15, 2026
- Decks
- 7 decks · latest September 2026
Where Lifeward Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LFWD · Home listing · This page | NASDAQ | United States | USD |
| gettex:2RW | gettex | Germany | EUR |
| LS Exchange:A12BMB | LS Exchange | Germany | EUR |
| BOATS:LFWD | BOATS | United States | USD |
| Lang & Schwarz:A12BMB | Lang & Schwarz | Germany | EUR |
| Munich:2RW | Munich | Germany | EUR |
Valuation
EV/sales 0.3× against a median of 15.1×: 3rd lowest of 10 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $5.86M USD
- P/E
- Loss
- EV/sales
- 0.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.1×
- Gross margin
- 31.5%
- Operating margin
- −121.5%
- Net margin
- −155.4%
- Debt to equity
- 0.3×
- Beta vs S&P 500
- 1.22
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Lifeward Ltd. · NASDAQ:LFWD | US$7.94M | US$5.86M | n/a | 0.3× | n/a | 1.1× | −155.4% | 0.3× | 1.22 |
| VVT Med Inc. · TSXV:VVTM | US$8.99M | US$8.99M | n/a | 93.6× | n/a | n/a | n/a | n/a | 1.16 |
| SpineGuard · EURONEXT:ALSGD | US$8.88M | US$9.65M | n/a | 2.3× | n/a | 1.8× | −55.0% | 0.3× | n/a |
| Pulsenmore Ltd. · TASE:PLSM | US$8.71M | US$2.27M | n/a | 0.2× | n/a | 0.3× | −39.6% | 0.0× | n/a |
| Conavi Medical Corp. · TSXV:CNVI | US$8.66M | US$8.89M | n/a | 15.1× | n/a | n/a | n/a | n/a | 0.36 |
| Allmed Solutions Ltd. · TASE:ALMD | US$8.42M | US$1.41M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | n/a |
| ReNerve Limited · ASX:RNV | US$8.04M | US$7.05M | n/a | 20.9× | n/a | 3.8× | n/a | 0.0× | n/a |
| IRIDEX Corporation · NASDAQ:IRIX | US$7.92M | US$11.69M | n/a | 0.2× | n/a | 3.0× | −6.9% | 2.8× | 0.90 |
| Clinical Laserthermia Systems AB Class B · OMXSTO:CLS_B | US$7.54M | US$7.16M | n/a | 5.8× | n/a | 1.6× | −314.6% | 0.0× | n/a |
| BioElectronics Corp. · OTC:BIEL | US$7.41M | US$23.70M | n/a | 46.4× | n/a | n/a | −104.3% | n/a | 2.45 |
| Airway Medix SA · GPW:AWM | US$6.73M | US$10.07M | n/a | 278× | n/a | n/a | n/a | n/a | n/a |
| Median of the others | US$8.23M | US$8.94M | 15.1× | 1.7× | −55.0% | 0.0× | 1.03 |
Forecasts
1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.
- Price target
- 20.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -5.02 · 1 analyst
- Revenue, year to Dec 2026
- 25.24M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Josh Hexter | Chief Executive Officer |
| Ronan Tsimerman | Chief Financial Officer |
| Craig Peters | Vice President of Sales |
| David Hexner | Vice President of Research and Development |
| Miri Pariente | Vice President of Operations, Regulatory and Quality |
| Ami Kraft | Executive Advisor to the CEO |
| Keith D. Rose | Chief Medical Officer |
| Mela Ikanovic | Deputy General Manager and Vice President of International Sales |
Board
| Director | Role |
|---|---|
| Bob Marshall | Chairman of the Board |
Events
Calls
| Call | When | Status |
|---|---|---|
| Lifeward (NASDAQ:LFWD) Q1 2026 Earnings Call | Fri, May 15, 2026 · 8:30 AM ET | Replay |
| Lifeward (NASDAQ:LFWD) Q4 2025 Earnings Call | Wed, Mar 18, 2026 · 8:30 AM ET | Replay |
| Lifeward (NASDAQ:LFWD) Q3 2025 Earnings Call | Fri, Nov 14, 2025 · 8:30 AM ET | Replay |
| Lifeward (NASDAQ:LFWD) Q2 2025 Earnings Call | Thu, Aug 14, 2025 · 8:30 AM ET | Replay |
| Lifeward (NASDAQ:LFWD) Q1 2025 Earnings Call | Thu, May 15, 2025 · 8:30 AM ET | Replay |
| Lifeward (NASDAQ:LFWD) Q4 2024 Earnings Call | Fri, Mar 07, 2025 · 8:30 AM ET | Replay |
| Lifeward (NASDAQ:LFWD) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 8:30 AM ET | Replay |
| Lifeward (NASDAQ:LFWD) Q2 2024 Earnings Call | Thu, Aug 15, 2024 · 8:30 AM ET | Replay |
| Lifeward (NASDAQ:LFWD) Q1 2024 Earnings Call | Wed, May 15, 2024 · 8:30 AM ET | Replay |
| Lifeward (NASDAQ:LFWD) Q4 2023 Earnings Call | Tue, Feb 27, 2024 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · Before open | −29.0% |
| Q2 2026 | Aug 14, 2026 · Before open | −5.6% |
| Q1 2026 | May 15, 2026 · Before open | +1.6% |
| Q4 2025 | Mar 18, 2026 · Before open | −11.1% |
| Q3 2025 | Nov 14, 2025 · Before open | +14.8% |
| Q2 2025 | Aug 14, 2025 · Before open | −14.6% |
| Q1 2025 | May 15, 2025 · Before open | −10.4% |
| Q4 2024 | Feb 25, 2025 · Before open | −0.6% |
| Q3 2024 | Nov 12, 2024 · Before open | +0.8% |
| Q2 2024 | Aug 14, 2024 · After close | +30.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · Before open | −2.7% |
| Q4 2023 | Feb 27, 2024 · Before open | +0.3% |
| Q3 2023 | Nov 14, 2023 · Before open | +2.4% |
| Q2 2023 | Aug 11, 2023 · Before open | −1.8% |
| Q1 2023 | May 11, 2023 · Before open | +1.0% |
| Q4 2022 | Feb 23, 2023 · Before open | −3.0% |
| Q3 2022 | Nov 7, 2022 · Before open | −2.8% |
| Q2 2022 | Aug 9, 2022 · Before open | 0.0% |
| Q1 2022 | May 13, 2022 · After close | −2.3% |
| Q4 2021 | Feb 24, 2022 · Before open | −1.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 17 slides | September 2026 |
| ReWalk Robotics — Investor Presentation (April 2024) | Investor deck | 26 slides | Apr 3, 2024 |
| ReWalk Robotics — Investor Presentation (October 2023) | Investor deck | 32 slides | Oct 13, 2023 |
| ReWalk Robotics — Merger or Acquisition (August 2023) | Merger or acquisition | 11 slides | Aug 9, 2023 |
| ReWalk Robotics — Investor Presentation (April 2023) | Investor deck | 31 slides | Apr 28, 2023 |
| ReWalk Robotics — IPO Roadshow (January 2020) | IPO roadshow | 28 slides | Jan 30, 2020 |
| ReWalk Robotics — Investor Presentation (November 2018) | Investor deck | 22 slides | Nov 13, 2018 |
Financings
| Raise | Date |
|---|---|
| Senior secured convertible notes and accompanying warrants Tranche closed: US$5.6M raised Use of proceeds: Accelerate commercialization of its restorative healthcare platform, expand its reimbursement-backed distribution model and advance its product portfolio | Jul 7, 2026 |
| Strategic investment of ordinary shares, prefunded warrants, convertible notes and warrants Announced: up to US$47M · additional warrants to acquire up to $7 million in ordinary shares of Lifeward Buyers: Oramed (up to a 49.99% equity ownership in Lifeward) Use of proceeds: Cash runway to profitability and selective investment in high-value innovation | Jan 13, 2026 |
| Public offering of ordinary shares and accompanying warrants Closed: US$2.6M raised · US$0.65 a share · Warrants at US$0.65 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Continuing commercial efforts, working capital and general corporate purposes | Jun 26, 2025 |
| Registered direct offering of ordinary shares and unregistered warrants Announced: about US$5M · US$2.75 a share · Warrants at US$2.75 for 36 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Continuing commercial efforts, working capital and general corporate purposes | Jan 7, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as ReWalk Robotics Ltd. Priced at US$12.00 a share on Sep 11, 2014.
- Price
- US$12.00 a share
- Shares offered
- 3,000,000 ordinary shares
- Offering size
- US$36 million
- Underwriters' option
- Up to 450,000 more shares
- Underwriters
- Barclays, Jefferies, Canaccord Genuity · In the order on the cover
- Shares delivered
- On or about Sep 17, 2014
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 16, 2014 |
| Filed publicly | Jul 10, 2014 |
| Amended 3 times | Newest Aug 26, 2014 |
| Shares registered with an exchange | Sep 2, 2014 |
| Declared effective by the SEC | Sep 11, 2014 |
| Final prospectus, with the price | Sep 15, 2014 |
Filings
| Filing | Filed |
|---|---|
| 424B1 · Prospectus | Sep 15, 2014 |
| FWP · Free writing prospectus | Sep 12, 2014 |
| EFFECT · Notice that a registration is effective | Sep 11, 2014 |
| CERTNAS · Nasdaq's certificate of listing | Sep 11, 2014 |
| CORRESP · Letter to the SEC | Sep 9, 2014 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 2, 2014 |
| F-1/A · Registration statement, amended | Aug 26, 2014 |
| CORRESP · Letter to the SEC | Aug 20, 2014 |
| F-1/A · Registration statement, amended | Aug 20, 2014 |
| CORRESP · Letter to the SEC | Jul 16, 2014 |
All 17 filings
| Filing | Filed |
|---|---|
| F-1/A · Registration statement, amended | Jul 16, 2014 |
| UPLOAD · Letter from the SEC | Jul 11, 2014 |
| F-1 · Registration statement | Jul 10, 2014 |
| DRSLTR · Letter to the SEC with a draft | Jun 25, 2014 |
| DRS/A · Draft registration statement, amended | Jun 25, 2014 |
| UPLOAD · Letter from the SEC | Jun 13, 2014 |
| DRS · Draft registration statement | May 16, 2014 |
Open IPO · From the cover of the final prospectus (424B1) filed Sep 15, 2014
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 22.0M | 25.7M | 13.9M | 5.51M | 5.97M | 4.39M |
| Cost of revenue | 13.6M | 17.4M | 9.40M | 3.61M | 3.06M | 2.20M |
| Gross profit | 8.43M | 8.22M | 4.45M | 1.91M | 2.90M | 2.19M |
| Research and development | 3.25M | 4.63M | 4.15M | 4.03M | 2.94M | 3.46M |
| Selling, general and administrative | 8.20M | 5.20M | 9.99M | 7.13M | 5.63M | 4.98M |
| Operating income | -19.7M | -29.3M | -23.6M | -19.1M | -12.7M | -12.0M |
| Depreciation and amortization | 333.0K | 494.0K | 239.0K | 202.0K | 266.0K | 285.0K |
| EBITDA | -19.3M | -28.9M | -23.4M | -18.9M | -12.4M | -11.7M |
| Interest expense | 295.0K | 128.0K | 20.0K | 22.0K | 0 | 907.0K |
| Income before tax | -20.0M | -28.9M | -22.1M | -19.1M | -12.6M | -12.9M |
| Income tax | -55.0K | 43.0K | -12.0K | 467.0K | 94.0K | 51.0K |
| Net income | -19.9M | -28.9M | -22.1M | -19.6M | -12.7M | -13.0M |
| Earnings per share, basic | -17.16 | -39.96 | -31.13 | -2.20 | -0.27 | -0.82 |
| Earnings per share, diluted | -17.16 | -39.96 | -31.13 | -2.20 | -0.27 | -0.82 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 | FY2022 | FY2021 | FY2021 | FY2020 | FY2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 2.17M | 6.75M | 28.1M | 28.1M | 67.9M | 67.9M | 88.3M | 88.3M | 20.4M | 20.4M |
| Receivables | 6.14M | 6.00M | 3.12M | 3.12M | 1.04M | 1.04M | 585.0K | 585.0K | 684.0K | 684.0K |
| Inventory | 5.73M | 6.72M | 5.65M | 5.65M | 2.93M | 2.93M | 2.99M | 2.99M | 3.54M | 3.54M |
| Current assets | 15.8M | 21.3M | 39.2M | 39.2M | 72.5M | 72.5M | 92.5M | 92.5M | 25.2M | 25.2M |
| Property, plant and equipment | 585.0K | 867.0K | 1.26M | 196.0K | 284.0K | 437.0K | ||||
| Goodwill | 4.75M | 7.54M | 7.54M | 7.54M | 0 | |||||
| Total assets | 22.9M | 30.5M | 63.2M | 63.2M | 74.2M | 74.2M | 94.8M | 94.8M | 28.1M | 28.1M |
| Accounts payable | 5.59M | 5.02M | 5.07M | 5.07M | 1.95M | 1.95M | 1.38M | 1.38M | 2.27M | 2.27M |
| Current liabilities | 12.0M | 10.2M | 11.8M | 11.8M | 4.78M | 4.78M | 4.04M | 4.04M | 4.67M | 4.67M |
| Total debt | 4.39M | 880.0K | 1.90M | 1.90M | 897.0K | 897.0K | 1.06M | 1.06M | 1.58M | 1.58M |
| Total liabilities | 14.5M | 11.6M | 16.7M | 16.7M | 6.07M | 6.07M | 5.37M | 5.37M | 6.29M | 6.29M |
| Shareholders' equity | 8.41M | 18.8M | 46.5M | 46.5M | 68.2M | 68.2M | 89.4M | 89.4M | 21.8M | 21.8M |
| Shares outstanding | 1.52M | 734.0K | 8.59M | 60.1M | 62.5M | 25.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -16.8M | -21.7M | -20.7M | -17.9M | -11.5M | -12.6M |
| Capital spending | -16.0K | 0 | -81.0K | -25.0K | -47.0K | -73.0K |
| Free cash flow | -16.8M | -21.7M | -20.7M | -17.9M | -11.5M | -12.7M |
| Cash from investing | -16.0K | 0 | -18.1M | -25.0K | -47.0K | -73.0K |
| Cash from financing | 12.2M | 0 | -992.0K | -2.50M | 79.5M | 16.7M |
| Share buybacks | 0 | 0 | -992.0K | -2.50M | 0 | |
| Change in cash | -4.53M | -21.7M | -39.8M | -20.5M | 68.0M | 4.06M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 3 · Initial statement of ownership | Nov 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 5, 2026 | Meeting outcome | SEC |
| 3 · Initial statement of ownership | Nov 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 27, 2026 | Management or board change | SEC |
| 8-K · Current report | Oct 8, 2026 | Management or board change | SEC |
| 8-K · Current report | Oct 1, 2026 | Management or board change | SEC |
| ARS · Annual report to shareholders | Sep 25, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Sep 25, 2026 | Meeting notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| PRE 14A · Preliminary proxy statement | Sep 15, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 15, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 31, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 24, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 20, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Aug 11, 2026 | Other filings | SEC |
| S-3 · Registration statement | Aug 3, 2026 | Offer document | SEC |
| D | Jul 8, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 7, 2026 | Material contract | SEC |
| SD · Specialized disclosure | May 29, 2026 | ESG report | SEC |
| S-8 · Registration statement for employee plans | May 20, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 20, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 20, 2026 | Insider trade | SEC |
| 8-K · Current report | May 19, 2026 | Current report | SEC |
| NT 10-Q · Late filing notice | May 15, 2026 | Explanation request | SEC |
| 8-K · Current report | May 15, 2026 | Results | SEC |
| 3 · Initial statement of ownership | May 14, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | May 14, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | May 13, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 8, 2026 | Other filings | SEC |
| DEL AM | May 8, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 1, 2026 | Other filings | SEC |
| S-3 · Registration statement | Apr 27, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 23, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 13, 2026 | Insider trade | SEC |
| D | Apr 2, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 31, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 25, 2026 | Acquisition or disposal | SEC |
| 8-K · Current report | Mar 20, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 18, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 18, 2026 | Results | SEC |
| 8-K · Current report | Mar 13, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Mar 11, 2026 | Current report | SEC |
| 8-K · Current report | Mar 2, 2026 | Current report | SEC |
| 8-K · Current report | Feb 27, 2026 | Management or board change | SEC |
| 8-K · Current report | Feb 25, 2026 | Financing | SEC |
| 8-K · Current report | Feb 19, 2026 | Material contract | SEC |
| DEFM14A | Feb 9, 2026 | Meeting notice | SEC |
| 8-K · Current report | Feb 9, 2026 | Current report | SEC |
| PREM14A | Jan 28, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 28, 2026 | Management or board change | SEC |
| 8-K · Current report | Jan 13, 2026 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Jan 7, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 6, 2026 | Meeting outcome | SEC |
| CORRESP · Letter to the SEC | Jan 2, 2026 | Other filings | SEC |
| S-3/A · Registration statement, amended | Jan 2, 2026 | Offer document | SEC |
| 8-K · Current report | Dec 19, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| DEF 14A · Proxy statement | Dec 1, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Nov 21, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| 8-K · Current report | Oct 16, 2025 | Results | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| S-8 POS | Aug 25, 2025 | Offer document | SEC |
| S-8 POS | Aug 25, 2025 | Offer document | SEC |
| S-8 POS | Aug 25, 2025 | Offer document | SEC |
| S-8 POS | Aug 25, 2025 | Offer document | SEC |
| S-8 POS | Aug 25, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Aug 25, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 13, 2025 | Management or board change | SEC |
| 8-K · Current report | Aug 8, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 5, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 1, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 26, 2025 | Material contract | SEC |
| DEF 14A · Proxy statement | Jun 26, 2025 | Meeting notice | SEC |
| 424B4 · Prospectus | Jun 26, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 26, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 25, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 23, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 23, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jun 20, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 16, 2025 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Jun 16, 2025 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Jun 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2025 | Management or board change | SEC |
| SD · Specialized disclosure | May 28, 2025 | ESG report | SEC |
| DRS · Draft registration statement | May 27, 2025 | Offer document | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | May 21, 2025 | Other filings | SEC |
| 8-K · Current report | May 19, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| S-3 · Registration statement | May 15, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 8-K · Current report | Apr 15, 2025 | Current report | SEC |
| 8-K · Current report | Apr 14, 2025 | Results | SEC |
| 8-K · Current report | Mar 7, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Mar 7, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 7, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 7, 2025 | Results | SEC |
| 8-K · Current report | Feb 20, 2025 | Results | SEC |
| EFFECT · Notice that a registration is effective | Feb 18, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Feb 14, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 14, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 13, 2025 | Other filings | SEC |
| S-1 · Registration statement | Feb 11, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 14, 2025 | Big-stake notice | SEC |
| D | Jan 13, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 8, 2025 | Insider trade | SEC |
| 8-K/A · Current report, amended | Jan 8, 2025 | Current report | SEC |
| 8-K · Current report | Jan 8, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jan 8, 2025 | Offer document | SEC |
| DEFA14A · Additional proxy material | Dec 27, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2024 | Insider trade | SEC |
| DEF 14A · Proxy statement | Nov 25, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Nov 15, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 3 · Initial statement of ownership | Nov 7, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 7, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 16, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 4, 2024 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Aug 26, 2024 | Meeting notice | SEC |
| 8-K · Current report | Aug 15, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Aug 9, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Aug 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 5, 2024 | Other filings | SEC |
| DEF 14A · Proxy statement | Jul 29, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jul 19, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 2, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 20, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| SD · Specialized disclosure | May 28, 2024 | ESG report | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2024 | Annual report | SEC |
| 4 · Change in ownership | Apr 22, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 22, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 19, 2024 | Management or board change | SEC |
| 8-K · Current report | Apr 4, 2024 | Current report | SEC |
| 8-K · Current report | Apr 3, 2024 | Current report | SEC |
| 10-K · Annual report | Feb 27, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2024 | Results | SEC |
| 8-K · Current report | Jan 30, 2024 | Current report | SEC |
| 8-K · Current report | Dec 19, 2023 | Current report | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 20, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2023 | Other filings | SEC |
| 4 · Change in ownership | Nov 16, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 8-K/A · Current report, amended | Oct 27, 2023 | Current report | SEC |
| 8-K · Current report | Oct 13, 2023 | Current report | SEC |
This page holds 200 of 866 filings. Open Filings
Cap table
Built by 6ix from Lifeward Ltd.’s releases · as of Jul 7, 2026
- Common shares
- 2,832,016
- Fully diluted
- 2,832,016
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 2,832,016 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.65 · expire about Jun 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 2,832,016 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Glenn P. Muir Other companies: Cytek Biosciences, Inc. (Director · Since at least Jun 10, 2026); Neuronetics, Inc. (Board Member · Since at least Jun 27, 2018); Repligen Corporation (Director · Since at least Sep 14, 2015); G1 Therapeutics Inc (Director · May 16, 2017 – Sep 18, 2024 · Past); Hologic Inc (Executive VP and CFO · Feb 1, 2006 – May 8, 2014 · Past) | Director · Dec 31, 2015 – Jun 27, 2017 · Past |
| Nadav Kidron Other companies: Nano Dimension Ltd (Director · Since at least Aug 16, 2026); Alpha Tau Medical Ltd (Director · Since at least May 12, 2025); Oramed Pharmaceuticals Inc. (President and CEO, Director · Since at least Feb 3, 2006) | Director · Since at least Mar 25, 2026 |
| Avraham Gabay Other companies: Oramed Pharmaceuticals Inc. (Chief Financial Officer · Since at least Jun 18, 2024); BiomX Inc. (Interim CFO · Dec 6, 2023 – Dec 6, 2023 · Past) | Director · Since at least Aug 20, 2026 |
| Hadar Levy Other companies: BrainsWay Ltd (Chief Executive Officer (CEO) · Since at least Mar 18, 2026) | Director · Since at least Aug 1, 2025 |
| Lawrence Jasinski Other companies: LeMaitre Vascular, Inc. (Board Director · Since at least Jul 26, 2010) | Chief Executive Officer, Director · Dec 31, 2015 – May 21, 2025 · Past |
| Michael Lawless Other companies: InspireMD Inc. (CFO · Since at least Jun 25, 2025) | Chief Financial Officer · Sep 19, 2022 – May 23, 2024 · Past |
| Miriam Kidron Other companies: Oramed Pharmaceuticals Inc. (Chief Scientific Officer, Director · Since at least Dec 31, 2025) | Director · Since at least Mar 25, 2026 |
| Moshe Rozenbaum Other companies: Nano Dimension Ltd (Interim CEO · Since at least Oct 26, 2026) | Director · Since at least Mar 25, 2026 |
| Robert J Marshall Jr Other companies: Lantheus Holdings, Inc. (CFO and Treasurer · Since at least Jun 9, 2025) | Director · Since at least Aug 1, 2025 |
| Yehuda Reznick Other companies: Oramed Pharmaceuticals Inc. (Director · Since at least Apr 1, 2024) | Director · Since at least Mar 25, 2026 |
All 30 people
| Person | Seat |
|---|---|
| Almog Adar | Chief Financial Officer · Since at least Mar 12, 2022 |
| Ami Kraft | Executive Advisor to the CEO · Since at least Nov 5, 2026 |
| Bob Marshall | Chairman of the Board · Since at least Dec 19, 2025 |
| Charles Remsberg | Chief Sales Officer · Aug 11, 2023 – Aug 11, 2023 · Past |
| Chunlin Han | Director · May 15, 2019 – May 15, 2019 · Past |
| Craig Peters | Vice President of Sales · Since at least Nov 5, 2026 |
| David Hexner | Vice President of Research and Development · Since at least Feb 25, 2026 |
| Haggai Zamir | Director · Since at least Aug 14, 2026 |
| Jeannine Lynch | VP of Market Access & Strategy · Since at least Aug 31, 2021 |
| John Vincent Hamilton | VP, Regulatory and Clinical · Jan 13, 2016 – Jul 25, 2016 · Past |
| Joseph E Turk Jr | Director · Since at least Apr 20, 2022 |
| Josh Hexter | Chief Executive Officer · Since at least Oct 14, 2026 |
| Keith D. Rose | Chief Medical Officer · Since at least May 1, 2026 |
| Mela Ikanovic | Deputy General Manager and Vice President of International Sales · Since at least Nov 5, 2026 |
| Miri Pariente | Vice President of Operations, Regulatory and Quality · Since at least Nov 5, 2026 |
| Randel Richner | Director · Since at least Nov 1, 2020 |
| Ronan Tsimerman | Chief Financial Officer · Since at least Nov 5, 2026 |
| William Mark Grant | President & CEO, Director · Since at least Jun 2, 2025 |
| William Mark Sigsbee | Director · Since at least Mar 25, 2026 |
| Yonason Greenwald | Director · Since at least Aug 14, 2026 |
Log in to ask 6ix AI your own questions about Lifeward Ltd.